MEA Migraine Drug Market

MEA Migraine Drugs Market Size (2024 to 2029)

The size of the Migraine Drugs Market in the Middle East and Africa is valued at USD 0.42 billion in 2024. It is estimated to be growing at a CAGR of 6.264% to reach USD 0.58 billion by 2029.

Factors such as growing awareness of new drug classes and increasing incidence of migraine problems across this region are expected to drive the migraine drugs market in MEA. Besides, the calcitonin gene-linked peptide (CGRP) launch is expected to drive the growth of this industry. In MEA, among these, South Africa is likely to emerge as a key opportunity in the global migraine drugs market. Elevated demand for migraine drugs, the formation of significant players in the region, and elevated emphasis on healthcare is estimated to drive significant market growth during the forecast period. The region is also seeing increased awareness of mental health in most areas and the cost-effectiveness of medical procedures. The increasing use of cost-effective preventive medicine may fuel migraine medications globally during the forecast period.

The migraine diagnosis rate is low, around 50% for episodic migraine, and 40% for chronic migraine. The KOLs said doctors often misdiagnosed migraine patients, mistaking them for cluster or tension headaches. The greatest unmet need that remains is the lack of medical education and training, which is unlikely to be met during the forecast period. 

This research report on the MEA migraine drugs market has been segmented and sub-segmented into the following categories.

• By Treatment: Preventive and Absorptive
• By Therapeutic Class: Triptants, Ergots, and Others
• By Country:  KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Regionally, The MEA migraine medication market is estimated to hike at a sluggish rate from 2020 to 2025. Treatments for migraine are aimed at stopping symptoms or preventing future attacks of migraine. It is a common neurovascular disease characterized by tender headaches and is usually associated with other neurological indications, such as nausea, vomiting, and painful tenderness lights and sounds. Migraine is more common in women than in men, mainly due to fluctuations in hormone levels. MEA is expected to dominate the global migraine drug market and continue this trend shortly. This strong growth is primarily due to the increasing number of people suffering from migraines and the increased public awareness of the disease in this region. Further, South Africa and Turkey are the major developing countries contributing to the global migraine drug market's growth in the MEA region. It is mainly due to the high incidence of migraine in these countries. The increasing focus on niche products and their launches and the increased penetration of new drug manufacturers will positively impact the growth of the MEA anti-migraine drugs market growth shortly.

The leading companies leading in the MEA Migraine Drugs Market profiled in the report are Winston Pharmaceuticals, Allergan, and Zogenix.NValeant, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, RedHill other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor. Key players in the market are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories.